Silverberg Bernstein Capital Management LLC Purchases 43,591 Shares of MediWound Ltd. $MDWD

Key Points

• Silverberg Bernstein Capital Management LLC increased its stake in MediWound Ltd. by 41.9%, acquiring an additional 43,591 shares to bring its total holding to 147,535 shares.
• Institutional investors collectively hold 46.83% of MediWound's stock, indicating significant interest from the financial sector.
• MediWound's recent earnings report showed a loss of ($1.23) per share, falling short of analysts' expectations, despite revenue slightly exceeding estimates.

Silverberg Bernstein Capital Management LLC boosted its position in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 41.9% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 147,535 shares of the biopharmaceutical company's stock after purchasing an additional 43,591 shares during the period. MediWound comprises 2.0% of Silverberg Bernstein Capital Management LLC's holdings, making the stock its 13th largest position. Silverberg Bernstein Capital Management LLC owned about 1.36% of MediWound worth $2,858,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers raised its position in MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock valued at $176,000 after purchasing an additional 481 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares during the period. Corebridge Financial Inc. boosted its holdings in MediWound by 17.1% in the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 665 shares during the period. Nuveen LLC bought a new stake in shares of MediWound during the 1st quarter worth $168,000. Finally, Deutsche Bank AG increased its position in shares of MediWound by 2,255.2% in the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company's stock valued at $98,000 after acquiring an additional 6,044 shares during the period. Institutional investors own 46.83% of the company's stock.

MediWound Price Performance

MDWD traded down $0.27 on Friday, hitting $16.98. The company had a trading volume of 97,848 shares, compared to its average volume of 152,918. The stock has a market cap of $183.55 million, a price-to-earnings ratio of -6.43 and a beta of 0.25. MediWound Ltd. has a 1-year low of $14.14 and a 1-year high of $22.50. The company's fifty day moving average price is $18.27 and its 200 day moving average price is $18.44.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.68). MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. The company had revenue of $5.71 million during the quarter, compared to the consensus estimate of $5.68 million. On average, sell-side analysts forecast that MediWound Ltd. will post -2.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MDWD. Wall Street Zen downgraded shares of MediWound from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Zacks Research lowered shares of MediWound from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Oppenheimer initiated coverage on shares of MediWound in a research note on Monday, June 2nd. They issued an "outperform" rating and a $34.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $32.25.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.